Proteomics

Dataset Information

0

B cell lymphocytes as a potential source of breast carcinoma marker candidates

ABSTRACT: The prognostic correlation of tumor-infiltrating T cells has been widely studied in breast cancer, but tumor-infiltrating B cells have not received so much attention. The protein profile analysis of CD19+ B-lymphocytes in benign, Luminal A, Luminal B, and triple-negative breast cancer patients in comparison to healthy control via a label-free proteomic quantification was performed. We aimed to find a correlation between immunohistochemical results and proteomic approach in measuring the expression of proteins isolated from B-cell lymphocytes in peripheral blood samples. We identified 18 proteins with a significant fold change of more than 2, that have promising potential to serve as breast cancer biomarkers in the future since they are already either confirmed or proposed markers isolated directly from cancer tissue.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): B Cell, Blood

DISEASE(S): Breast Cancer

SUBMITTER: Miroslav Marcin  

LAB HEAD: Ján Sabo

PROVIDER: PXD052185 | Pride | 2025-09-22

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20230619_metoda17_Z23B_meranie1_healthy.raw Raw
20230619_metoda17_Z6B_meranie1_healthy.raw Raw
20230620_metoda17_Z10B_meranie1_healthy.raw Raw
20230620_metoda17_Z14B_meranie1_healthy.raw Raw
20230620_metoda17_Z15B_meranie1_healthy.raw Raw
Items per page:
1 - 5 of 57
altmetric image

Publications

B Cell Lymphocytes as a Potential Source of Breast Carcinoma Marker Candidates.

Tkáčiková Soňa S   Marcin Miroslav M   Bober Peter P   Kacírová Mária M   Šuliková Michaela M   Parnica Jozef J   Tóth Dávid D   Lenárt Marek M   Radoňak Jozef J   Urdzík Peter P   Fedačko Ján J   Sabo Ján J  

International journal of molecular sciences 20240704 13

Despite advances in the genomic classification of breast cancer, current clinical tests and treatment decisions are commonly based on protein-level information. Nowadays breast cancer clinical treatment selection is based on the immunohistochemical (IHC) determination of four protein biomarkers: Estrogen Receptor 1 (ESR1), Progesterone Receptor (PGR), Human Epidermal Growth Factor Receptor 2 (HER2), and proliferation marker Ki-67. The prognostic correlation of tumor-infiltrating T cells has been  ...[more]

Similar Datasets

Proteomics Peripheral Blood CD8+ T-Lymphocyte Immune Response in Benign and Subpopulations of Breast Cancer Patients
2024-07-09 | PXD051985 | Pride
Transcriptomics Transcriptomic survey of lymph node-positive vs. - negative ductal breast cancer
2013-03-05 | E-GEOD-44408 | biostudies-arrayexpress
Genomics Homo sapiens
| PRJNA925311 | ENA
Transcriptomics Tumor-infiltrating lymphocytes, prognosis and trastuzumab benefit in early-stage breast cancer patients from the FinHER trial
2022-07-16 | GSE47994 | GEO
Methylation profiling Epigenome analysis of normal ductal breast samples and infiltrating ductal breast cancer (BC) classified by tumour subtype
2020-02-17 | GSE141338 | GEO
Transcriptomics Affymetrix HG-U133A gene expression profiles of 39 human breast cancer cell lines
2009-07-13 | E-GEOD-16795 | biostudies-arrayexpress
Transcriptomics Non-cancerous liver infiltrating lymphocytes of hepatitis C and tumor-infiltrating lymphocytes
2010-06-25 | E-GEOD-10461 | biostudies-arrayexpress
Transcriptomics Affymetrix HG-U133A gene expression profiles of 39 human breast cancer cell lines
2009-07-13 | GSE16795 | GEO
Proteomics Proteomic changes of CD19+ B Lymphocytes in COVID-19 Patients
2023-09-24 | PXD042938 | Pride
Transcriptomics Expression data from MCF7 Scrambled and SIM2si cells
2013-02-08 | E-GEOD-44187 | biostudies-arrayexpress